Compression therapy is considered the gold standard of care for managing lower extremity oedema and venous ulceration1.
3M advanced the science of compression therapy by creating materials engineered to deliver Intelligent Compression Dynamics to provide comfortable, therapeutic compression for the management of venous leg ulcers. 3M™ Coban™ 2 Compression System provides a comfortable, rigid sleeve that consistently delivers the right amount of compression to reduce oedema.
Patients can wear normal clothing and shoes because the patented interlocking materials are designed to reduce the potential for uncomfortable slipping or bunching. Coban 2 compression system is much less bulky compared to 4 layer compression systems.
Coban 2 compression system is designed to reduce application variability for consistent compression every time.
It has been shown that venous leg ulcers (VLUs) can have a devastating impact to a patient's quality of life. 81 percent of patients with VLUs experience decreased mobility, and 50% report severely limited mobility. Additionally, 68 percent of patients with impaired mobility experience fear, anger, depression and social isolation.2
Learn how you can help patients combat venous insufficiency to promote healing, improve comfort, reduce costs and elevate health-related quality of life.
Compression therapy is known to significantly increase venous leg ulcer healing rates and reduce the risk of recurrence.3,4 However compression therapy remains underused. To drive deeper understanding and wider adoption of compression therapy, an international group of experts in leg ulcers and venous disease developed a simplified approach presented as an ABC of the management of VLUs.
In a study of patients whose venous leg ulcers had not responded to conventional compression bandaging, Coban 2 compression system was found to achieve faster reduction in oedema, pain, and exudation with each clinic assessment than traditional multi-layer compression systems. Seventy-five percent of patients reduced their ulcer surface area between 30-40% within the four week trial period.5
Lymphoedema is a swelling that develops as a result of an impaired lymphatic system. This may be as a result of the lymphatic system not developing properly or through damage or trauma. It can occur anywhere in the body, at multiple sites or localised. It depends on where there is an impairment in the lymphatic vessels. Recent research suggests that lymphoedema affects at least 240,000 men, women and children in the UK (Lymphoedema Support Network).